AI Article Synopsis

  • This study evaluated how certain biomarkers from pretreatment PET/CT scans relate to patient outcomes in those with metastatic breast cancer (mBC) receiving specific antibody-drug conjugates (ADCs) - Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan (T-DXd).
  • Conducted on 128 patients, the research found that higher levels of total metabolic tumor volume (TMTV) and maximum tumor dissemination (Dmax) were linked to shorter overall survival (OS) and progression-free survival (PFS) in both treatment groups.
  • The conclusion highlights the potential of these biomarkers for improving survival predictions and tailoring treatment plans for mTNBC and

Article Abstract

Purpose: This study aimed to evaluate the association between pretreatment [18F]FDG PET/CT-derived biomarkers and outcomes in metastatic breast cancer (mBC) patients treated with antibody-drug conjugates (ADCs) Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan (T-DXd).

Methods: A retrospective bicentric analysis was conducted on triple-negative mBC (mTNBC) patients treated with SG and HER2-low mBC patients treated with T-DXd, who underwent [18F]FDG PET/CT scans before therapy. Key biomarkers, including maximum standardized uptake value (SUVmax), total metabolic tumor volume (TMTV) and maximum tumor dissemination (Dmax), were measured. Their prognostic value for progression-free survival (PFS) and overall survival (OS) was assessed using Cox models and Kaplan-Meier curves.

Results: 128 patients were included: 71 mTNBC treated with SG and 57 HR-positive and -negative HER2-low mBC treated with T-DXd. Median follow-up was 12.9 months. In the SG cohort, median PFS and OS were 4.8 and 8.9 months, respectively. High Dmax (HR 2.1, 95% CI 1.1-4.3) and high TMTV (HR 2.9, 95% CI 1.2-6.6) were independently associated with shorter OS. In the T-DXd cohort, median PFS and OS were 5.8 and 9.0 months, respectively. High Dmax (HR 2.1, 95% CI 1.2-3.9) and high TMTV (HR 2.4, 95% CI 1.0-6.5) independently correlated with shorter PFS and shorter OS, respectively.

Conclusion: Pretreatment [18F]FDG PET/CT-derived biomarkers, namely TMTV and Dmax, have significant prognostic value in patients with mTNBC and HER2-low mBC treated with SG and T-DXd. These biomarkers improve prognostic prediction and may optimize treatment strategies, warranting their clinical use, but larger studies are needed to validate these findings.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-024-06929-xDOI Listing

Publication Analysis

Top Keywords

patients treated
12
her2-low mbc
12
treated t-dxd
12
[18f]fdg pet/ct
8
antibody-drug conjugates
8
metastatic breast
8
breast cancer
8
pretreatment [18f]fdg
8
[18f]fdg pet/ct-derived
8
pet/ct-derived biomarkers
8

Similar Publications

TiRobot-assisted versus freehand femoral neck system placement in the treatment of femoral neck fractures: a systematic review and meta-analysis.

J Robot Surg

January 2025

The Third Ward of Orthopaedic Department, General Hospital of Ningxia Medical University, 804 Shengli South Street, Hui Autonomous Region, Yinchuan, Ningxia, 750004, People's Republic of China.

The purpose of this study is to assess the safety and effectiveness of TiRobot-assisted treatment for femoral neck fractures, in comparison to traditional freehand treatment methods. Throughout the research process, we conducted an extensive literature search across numerous databases, including PubMed, EMBASE, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), CQVIP, and Wanfang. Based on the literature screening criteria, we selected six studies, encompassing 358 cases of femoral neck fracture patients, for this meta-analysis.

View Article and Find Full Text PDF

Purpose: Age stratification influences the clinicopathological features and survival outcomes of breast cancer. We aimed to understand the effect of age on gene variants in young Chinese women with breast cancer compared with those from The Cancer Genome Atlas (TCGA).

Methods: Enrolled patients ≤ 40 years old (N = 370) underwent germline or somatic genetic testing using a 32-gene hereditary cancer panel at Fujian Union Hospital.

View Article and Find Full Text PDF

Purpose: There is an increasing incidence of young breast cancer (YBC) patients with uncertainty surrounding the factors and patterns that are contributing.

Methods: We obtained characteristics and survival data from 206,156 YBC patients (≤ 40 years of age) diagnosed between 2005 and 2019 from the National Cancer Database (NCDB). Patients were subdivided into two comparison groups based on year of diagnosis (2005-2009, Old vs.

View Article and Find Full Text PDF

Introduction: Laryngeal chondrosarcoma (CS) is a rare indolent malignant tumor. High-grade (G3), dedifferentiated (DD), and myxoid (MY) CSs are considered more aggressive subtypes due to their metastatic potential and relatively poor outcomes. The aim of this systematic review is to evaluate treatment modalities and survival outcomes in patients affected by these rarer CS subtypes.

View Article and Find Full Text PDF

More micrometastases, more recurrence? The role of qPCR of PSA mRNA in lymph nodes during prostatectomy.

World J Urol

January 2025

Department of Urology, Urooncology, Robot-assisted and Focal Therapy, University Hospital Magdeburg, Otto-von Guericke University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.

Background And Objectives: Radical prostatectomy is a standard treatment for prostate cancer, yet about 30% of patients experience rising biochemical markers within a decade post-surgery. Pelvic lymph node sampling during prostatectomy assesses potential lymph node metastases, but standard histological assessments, which typically examine only 2-3 tissue sections, often miss occult metastases. This study assesses the effectiveness of qPCR in detecting PSA coding KLK3 mRNA for identifying lymph node metastases post-prostatectomy and explores the correlation between PSA-mRNA and biochemical recurrence.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!